0.65Open0.65Pre Close0 Volume878 Open Interest310.00Strike Price0.00Turnover61.38%IV22.78%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier18DDays to Expiry0.65Extrinsic Value100Contract SizeAmericanOptions Type0.0795Delta0.0043Gamma215.33Leverage Ratio-0.1416Theta0.0093Rho17.12Eff Leverage0.0830Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet